JPH09502990A - アントラサイクリン二糖類、それらの調製方法、およびそれらを含む医薬組成物 - Google Patents
アントラサイクリン二糖類、それらの調製方法、およびそれらを含む医薬組成物Info
- Publication number
- JPH09502990A JPH09502990A JP7510106A JP51010695A JPH09502990A JP H09502990 A JPH09502990 A JP H09502990A JP 7510106 A JP7510106 A JP 7510106A JP 51010695 A JP51010695 A JP 51010695A JP H09502990 A JPH09502990 A JP H09502990A
- Authority
- JP
- Japan
- Prior art keywords
- group
- lyxo
- exopyranosyl
- dideoxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 27
- 229940045799 anthracyclines and related substance Drugs 0.000 title description 7
- 150000002016 disaccharides Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- -1 p-nitrobenzoyloxy Chemical group 0.000 claims description 8
- YOFDHOWPGULAQF-UHFFFAOYSA-N Daunomycin-Aglycone Natural products C1C(O)(C(C)=O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- YOFDHOWPGULAQF-MQJDWESPSA-N (7s,9s)-9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@@](O)(C(C)=O)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-MQJDWESPSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 claims description 5
- IBZGBXXTIGCACK-CWKPULSASA-N Adriamycinone Chemical compound C1[C@@](O)(C(=O)CO)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O IBZGBXXTIGCACK-CWKPULSASA-N 0.000 claims description 5
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004280 Sodium formate Substances 0.000 claims description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000474 mercury oxide Inorganic materials 0.000 claims description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019254 sodium formate Nutrition 0.000 claims description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 claims description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 230000031709 bromination Effects 0.000 claims 2
- 238000005893 bromination reaction Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- RBWNDBNSJFCLBZ-UHFFFAOYSA-N 7-methyl-5,6,7,8-tetrahydro-3h-[1]benzothiolo[2,3-d]pyrimidine-4-thione Chemical compound N1=CNC(=S)C2=C1SC1=C2CCC(C)C1 RBWNDBNSJFCLBZ-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 229940069417 doxy Drugs 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 150000004679 hydroxides Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 claims 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000005858 glycosidation reaction Methods 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 125000003563 glycoside group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VVKMHTWFAUCCOD-UHFFFAOYSA-N 1-(3-aminopropyl)-8-[3-[2-(dimethylamino)-2-oxoethyl]anilino]-n-[(2-methylpyridin-4-yl)methyl]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical group CN(C)C(=O)CC1=CC=CC(NC=2N=C3C=4N(CCCN)N=C(C=4CCC3=CN=2)C(=O)NCC=2C=C(C)N=CC=2)=C1 VVKMHTWFAUCCOD-UHFFFAOYSA-N 0.000 description 1
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MFSIEROJJKUHBQ-UHFFFAOYSA-N O.[Cl] Chemical compound O.[Cl] MFSIEROJJKUHBQ-UHFFFAOYSA-N 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical group [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 229930190071 lycoside Natural products 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- JUHDUIDUEUEQND-UHFFFAOYSA-N methylium Chemical compound [CH3+] JUHDUIDUEUEQND-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式(I)および(II)の化合物、並びにそれらの医薬上許される塩。 (式中、 RはHもしくはOHまたはOR7基(R7はCHOもしくはCOCH3または6個まで の炭素原子を含むカルボン酸のアシル基である)であり、 R1はH、OHまたはOCH3であり、 R2はHまたはFであり、 R3はHまたはOHであり、 R4およびR5は、同じであり、または異なり、それぞれH、OHまたはNH2 であり、 またはエカトリアルの位置にあり得ることを示す) 2.a)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ- エキソピラノシル)-α-L-リキソ-エキソピラノシル]ダウノルビシノンクロルヒ ドレート、 b)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-アラビノ-エキソピラノシル]ダウノルビシノンクロルヒ ドレート c)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-リキソ-エキソピラノシル]ドキソルビシノンクロルヒド レート、 d)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-アラビノ-エキソピラノシル]ドキソルビシノンクロルヒ ドレート、 e)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-アラビノ-エキソピラノシル]-4-デメトキシ-ダウノルビ シノンクロルヒドレート、 f)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-リキソ-エキソピラノシル]-4-デメトキシ-ダウノルビシ ノンクロルヒドレート、 g)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-リキソ-エキソピラノシル]-4-デメトキシ-ドキソルビシ ノンクロルヒドレート、 h)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-アラビノ-エキソピラノシル]-4-デメトキシ-ドキソルビ シノンクロルヒドレート、 i)7-0-[2,6-ジデオキシ-4-0-(2,3,4,6-テトラデオキシ-4-アミノ-α-L-エリ スロ-エキソピラノシル)-α-L-リキソ-エキソピラノシル]ダウノルビシノンク ロルヒドレート、 j)7-0-[2,6-ジデオキシ-4-0-(2,3,4,6-テトラデオキシ-4-アミノ-α-L-エリ スロ-エキソピラノシル)-α-L-リキソ-エキソピラノシル]-4-デメトキ シ-ダウノルビシノンクロルヒドレート、 k)7-0-[2,6-ジデオキシ-4-0-(2,3,4,6-テトラデオキシ-4-アミノ-α-L-エリ スロ-エキソピラノシル)-α-L-リキソ-エキソピラノシル]ドキソルビシノンク ロルヒドレート、 l)7-0-[2,6-ジデオキシ-4-0-(2,3,4,6-テトラデオキシ-4-アミノ-α-L-エリ スロ-エキソピラノシル)-α-L-リキソ-エキソピラノシル]-4-デメトキシ-ドキ ソルビシノンクロルヒドレート、 m)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-リキソ一エキソピラノシル]-4-デメトキシ-8-フルオロ- ダウノルビシノンクロルヒドレート及び n)7-0-[2,6-ジデオキシ-4-0-(2,3,6-トリデオキシ-3-アミノ-α-L-リキソ-エ キソピラノシル)-α-L-リキソ-エキソピラノシル]-4-デメトキシ-8-フルオロ- ドキソルビシノンクロルヒドレート からなる群に属する請求項1に記載の式(I)および(II)の化合物。 3.一般式(I)および(II)の化合物またはそれらの医薬上許される塩の調製方法 であって、 (式中、 RはHもしくはOHまたはOR7基(R7はCHOもしくはCOCH3または6個まで の炭素原子を含むカルボン酸のアシル基である)であり、 R1はH、OHまたはOCH3であり、 R2はHまたはFであり、 R3はHまたはOHであり、 R4およびR5は、同じであり、または異なり、それぞれH、OHまたはNH2 であり、 またはエカトリアルの位置にあり得ることを示す) 下記の工程: i)式(III)の化合物 (式中、R1およびR2は上記のとおりであり、かつR6はHまたはOR7基(R7 はアセチル基、ジメチルターブチルシリル基またはp-メトキシフェニルジフェ ニルメチル基の中から選ばれた、アルコール官能基の保護基である)である) と、式(IV)または(V)の化合物 (式中、R8はHまたは保護された-OH基であり、R9およびR10は同じであり 、または異なり、それぞれがH、保護された-OH基または保護されたNH2基であり 、かつXはハロゲンまたはp-ニトロベンゾイルオキシ基から選ばれた基である) との縮合、こうして式(VI)または(VII)の化合物を得、 義されたとおりである) ii)式(VI)および(VII)の化合物からOH官能基および/またはNH2官能基の保 護基を除去して式(I)および(II)の化合物(式中、R、R1、R2、R3、 は複数の反応、 iii)必要により、式(I)および(II)の化合物の、医薬上許される塩への変換 からなる上記の化合物の調製方法。 4.下記の工程: i)式(I)および(II)の化合物またはそれらの医薬上許される塩(式中、R1、 かつRはHである)の14位の炭素の臭素化、ならびに ii)得られた14−ブロモ誘導体を加水分解し、式(I)および(II)の化合物(式中 、R1、R2、R3、R4、R5は先に定義されたとおりであり、かつRはOH基で ある)を得ること からなる、請求項1に記載の式(I)および(II)の化合物(式中、R1、R2、R3 、R4、R5は先に定義されたとおりであり、かつRはOH基である)、またはそ れらの医薬上許される塩の調製方法。 5.工程iの式(IV)または(V)の化合物において、R8がHまたは保護されたOH 基、例えば、p-ニトロベンゾエートであり、R9およびR10が同じであり、また は異なり、それぞれがHまたは保護されたOH基、例えば、p-ニトロベンゾイル 基またはトリフルオロアセトチル基もしくはアリルオキシカルボニル基により保 護されたNH2基である請求項3に記載の方法。 6.工程i)が、銀トリフレート、過塩素酸銀、酸化水銀と臭化水銀との混合物、 トリメチルシリルトリフレート、p-トルエンスルホン酸、トリフルオロ酢酸、ホ ウ素ハロゲン化物、四塩化スズ、四塩化チタンまたはアンバーライト型のイオン 交換樹脂からなる群から選ばれた縮合剤の存在下で行われる請求項3に記載の方 法。 7.式(III)の化合物が不活性有機溶媒に溶解され、縮合が脱水物質としてのモ レキュラーシーブの存在下で行われる請求項3および6に記載の方法。 8.縮合中にピリジン、コリジン、N,N-ジメチルアミノピリジン、トリエチルア ミンまたは1,8-ビス-(ジメチルアミノ)-ナフタレンからなる群から選ばれた有機 塩基で反応混合物に添加される請求項6および7に記載の方法。 9.工程i)の前記ハロゲンが塩素または臭素である請求項3に記載の方法。 10.工程ii)において、NH2官能基を保護するトリフルオロアセチル基、および/ またはOH官能基を保護するp-ニトロベンゾイル基および/またはアセチル基が 、ナトリウム、カリウム、リチウムまたはバリウムの水酸化物または炭酸塩から なる群から選ばれた無機塩基の作用により除去される請求項3に記載の方法。 11.工程ii)において、NH2官能基を保護するアリルオキシカルボニル基がニッ ケルまたはパラジウム有機錯体の作用により除去される請求項3に記載の方法。 12.工程ii)において、OH官能基を保護するメトキシフェニルジフェニルメチ ル基が有機酸の作用により除去される請求項3に記載の方法。 13.前記有機酸が酢酸である請求項12に記載の方法。 14.工程ii)において、OH官能基を保護するジメチルターブチルシリル基がテ トラブチルアンモニウムフルオリドの存在下で除去される請求項3に記載の方法 。 15.工程iii)において、式(I)および(II)の化合物が医薬上許されるクロルヒド レートに変換される請求項3に記載の方法。 16.工程i)において、臭素化がクロロホルム中で臭素を用いて行われる請求項4 に記載の方法。 17.工程ii)において、加水分解がギ酸ナトリウムを用いて行われる請求項4に 記載の方法。 18.活性成分として少なくとも請求項1および2に記載の化合物またはその医薬 上許される塩を、医薬上許される担体または希釈剤と組み合わせて含んでなる医 薬組成物。 19.請求項1および2に記載の化合物またはその医薬上許される塩の抗癌剤とし ての使用。 20.活性成分として少なくとも請求項1および2に記載の化合物またはその医薬 上許される塩を、医薬上許される担体または希釈剤と組み合わせて含んでなる、 抗癌剤として作用する医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI930187A IT1262565B (it) | 1993-09-30 | 1993-09-30 | Disaccaridi di antracicline, loro processi di preparazione e composizioni farmaceutiche che li contengono. |
IT93A000187 | 1993-09-30 | ||
PCT/EP1994/003201 WO1995009173A1 (en) | 1993-09-30 | 1994-09-26 | Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502990A true JPH09502990A (ja) | 1997-03-25 |
JP3836503B2 JP3836503B2 (ja) | 2006-10-25 |
Family
ID=11350615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51010695A Expired - Fee Related JP3836503B2 (ja) | 1993-09-30 | 1994-09-26 | アントラサイクリン二糖類、それらの調製方法、およびそれらを含む医薬組成物 |
Country Status (27)
Country | Link |
---|---|
US (1) | US5801152A (ja) |
EP (1) | EP0721456B1 (ja) |
JP (1) | JP3836503B2 (ja) |
KR (1) | KR100341166B1 (ja) |
CN (1) | CN1042032C (ja) |
AT (1) | ATE178901T1 (ja) |
AU (1) | AU688374B2 (ja) |
BG (1) | BG62289B1 (ja) |
BR (2) | BR9407679A (ja) |
CZ (1) | CZ288462B6 (ja) |
DE (1) | DE69417907T2 (ja) |
DK (1) | DK0721456T3 (ja) |
ES (1) | ES2132429T3 (ja) |
FI (1) | FI113541B (ja) |
GE (1) | GEP20002095B (ja) |
GR (1) | GR3030731T3 (ja) |
HU (1) | HU227309B1 (ja) |
IT (1) | IT1262565B (ja) |
NO (1) | NO305400B1 (ja) |
NZ (1) | NZ273624A (ja) |
PL (1) | PL179399B1 (ja) |
RO (1) | RO115525B1 (ja) |
RU (1) | RU2144540C1 (ja) |
SK (1) | SK281797B6 (ja) |
TW (1) | TW404950B (ja) |
UA (1) | UA41951C2 (ja) |
WO (1) | WO1995009173A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1271689B (it) * | 1994-08-04 | 1997-06-04 | Menarini Farma Ind | 8-fluoro-antracicline, loro processi di preparazione e composizioni farmaceutiche che le contengono |
IT1307846B1 (it) * | 1999-03-09 | 2001-11-19 | Menarini Ricerche Spa | L-arabino disaccaridi di antracicline, loro processi di preparazione ecomposizioni farmaceutiche che li contengono. |
CN112010913B (zh) * | 2019-05-31 | 2022-06-21 | 南京正大天晴制药有限公司 | 4-脱氧柔红霉素的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561507A (en) * | 1976-11-17 | 1980-02-20 | Farmaceutici Italia | Snthracycline disaccharides |
US4201773A (en) * | 1978-07-26 | 1980-05-06 | The United States Of America As Represented By The Department Of Health, Education And Welfare | 7-O-(2,6-Dideoxy-α-L-lyxo-hexopyranosyl)-daunomycinone, desmethoxy daunomycinone, adriamycinone, and carminomycinone |
DE3641833A1 (de) * | 1986-12-08 | 1988-06-09 | Behringwerke Ag | Zytostatisch wirksame anthracyclinderivate |
US4918172A (en) * | 1987-10-06 | 1990-04-17 | Sanraku Incorporated | Anthracycline antibiotics |
AU4752190A (en) * | 1988-12-28 | 1990-08-01 | Board Of Regents, The University Of Texas System | 3'-deamino analogs of esorubicin and methods for their use |
IT1241927B (it) * | 1990-05-14 | 1994-02-01 | Menarini Farma Ind | 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono |
WO1992007862A1 (en) * | 1990-10-30 | 1992-05-14 | Yale University | Antibiotics improved by conjugation with stereospecific carbohydrtes and methods for carbohydrate stereoselectivity |
-
1993
- 1993-09-30 IT ITFI930187A patent/IT1262565B/it active IP Right Grant
-
1994
- 1994-09-26 PL PL94313708A patent/PL179399B1/pl not_active IP Right Cessation
- 1994-09-26 BR BR9407679A patent/BR9407679A/pt not_active Application Discontinuation
- 1994-09-26 HU HU9600812A patent/HU227309B1/hu not_active IP Right Cessation
- 1994-09-26 AU AU76986/94A patent/AU688374B2/en not_active Ceased
- 1994-09-26 CZ CZ1996904A patent/CZ288462B6/cs not_active IP Right Cessation
- 1994-09-26 DK DK94927649T patent/DK0721456T3/da active
- 1994-09-26 NZ NZ273624A patent/NZ273624A/en not_active IP Right Cessation
- 1994-09-26 UA UA96031231A patent/UA41951C2/uk unknown
- 1994-09-26 AT AT94927649T patent/ATE178901T1/de active
- 1994-09-26 WO PCT/EP1994/003201 patent/WO1995009173A1/en active IP Right Grant
- 1994-09-26 SK SK396-96A patent/SK281797B6/sk not_active IP Right Cessation
- 1994-09-26 EP EP94927649A patent/EP0721456B1/en not_active Expired - Lifetime
- 1994-09-26 RU RU96110287A patent/RU2144540C1/ru not_active IP Right Cessation
- 1994-09-26 CN CN94194276A patent/CN1042032C/zh not_active Expired - Lifetime
- 1994-09-26 KR KR1019960701668A patent/KR100341166B1/ko not_active IP Right Cessation
- 1994-09-26 RO RO96-00687A patent/RO115525B1/ro unknown
- 1994-09-26 DE DE69417907T patent/DE69417907T2/de not_active Expired - Lifetime
- 1994-09-26 ES ES94927649T patent/ES2132429T3/es not_active Expired - Lifetime
- 1994-09-26 JP JP51010695A patent/JP3836503B2/ja not_active Expired - Fee Related
- 1994-09-26 GE GEAP19943110A patent/GEP20002095B/en unknown
-
1995
- 1995-03-28 TW TW084103178A patent/TW404950B/zh not_active IP Right Cessation
-
1996
- 1996-03-15 NO NO961061A patent/NO305400B1/no not_active IP Right Cessation
- 1996-03-28 US US08/644,602 patent/US5801152A/en not_active Expired - Lifetime
- 1996-03-29 BG BG100466A patent/BG62289B1/bg not_active Expired - Lifetime
- 1996-03-29 FI FI961423A patent/FI113541B/fi not_active IP Right Cessation
-
1997
- 1997-05-13 BR BR1100550-5A patent/BR1100550A/pt active IP Right Grant
-
1999
- 1999-07-09 GR GR990401810T patent/GR3030731T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6328077B2 (ja) | ||
JPH0660191B2 (ja) | 新規アントラサイクリングリコシド類,それらの製造方法及びそれらを含む抗腫瘍剤 | |
JPH09502990A (ja) | アントラサイクリン二糖類、それらの調製方法、およびそれらを含む医薬組成物 | |
EP0230013B1 (en) | New anthracycline derivatives, uses thereof as antitumor agent and production thereof | |
JPS58198455A (ja) | (−)−15−デオキシスパガリンおよびその製造法並びにその中間体 | |
JPH10503509A (ja) | 8−フルオロ−アントラサイクリン類、それらの調整法及びそれらを含む薬学的組成品 | |
JP4615712B2 (ja) | 5−イミノ−13−デオキシアントラサイクリン誘導体、その使用、及び、その調製方法 | |
CA2173158C (en) | Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them | |
GB2215332A (en) | 4-Demethyl-4-0-(p-fluorobenzensulfonyl) anthracycline glycosides | |
JP2584479B2 (ja) | 新規なアンスラサイクリン誘導体とその製造法 | |
JPH01153694A (ja) | 新規4‐デメトキシアントラサイクリン誘導体 | |
HRP950092A2 (en) | Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them | |
GB2201419A (en) | Anthracycline-oestrone derivatives | |
JP2584486B2 (ja) | 新規なアンスラサイクリン誘導体とその製造法 | |
JPH0912590A (ja) | 4−アミノ−2,4,6−トリデオキシ−2−フルオロ−マンノピラノシル基を有する新規アンスラサイクリン誘導体 | |
JP2002539133A (ja) | アントラサイクリンのl−アラビノ−二糖類、その製造方法およびそれを含有する医薬組成物 | |
JPH01203397A (ja) | 新規なアンスラサイクリン誘導体とその製造法 | |
JPH0113717B2 (ja) | ||
JPS6328437B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060727 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090804 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100804 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100804 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110804 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120804 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120804 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130804 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |